Compound profile
MOTS-c
EmergingAlso known as: mitochondrial ORF of the 12S rRNA type-c
A mitochondria-derived peptide researched for metabolic regulation and exercise-related stress responses. Still early relative to incretin drugs, but frequently searched in biohacking circles.
Overview
MOTS-c is a 16-amino-acid peptide with an unusual origin story: it is encoded directly within mitochondrial DNA, specifically inside the gene for the mitochondrial 12S ribosomal RNA, rather than by nuclear DNA the way most peptide hormones are. It was identified and described in 2015 by Changhan Lee, working in Pinchas Cohen's laboratory at the University of Southern California, and the discovery was notable because it was among the first evidence that mitochondria, normally thought of purely as the cell's energy-producing organelles, can generate their own signaling peptides that act on the rest of the body.
The founding research, published in Cell Metabolism, described MOTS-c as a regulator of metabolic homeostasis in mice, showing it could help prevent diet-induced obesity and insulin resistance. Follow-up work from the same research group and others has studied MOTS-c in the context of exercise physiology, reporting that acute exercise substantially raises MOTS-c levels in skeletal muscle and, to a lesser degree, in circulation, and that levels decline with age in humans.
MOTS-c sits well behind more clinically developed metabolic peptides in terms of evidence. As of this review, there are no completed, published human efficacy trials testing MOTS-c administration in people, meaning that essentially everything known about its metabolic and longevity effects comes from mouse studies and human observational work looking at how MOTS-c naturally rises and falls with exercise and age, not from controlled human dosing trials.
Mechanism (plain language)
Encoded in mitochondrial DNA; studied for effects on AMPK-related pathways, insulin sensitivity, and metabolic homeostasis in preclinical models.
How it works
MOTS-c's primary proposed mechanism runs through AMP-activated protein kinase (AMPK), the cell's central energy sensor, which activates when the ratio of AMP to ATP rises, signaling that a cell is running low on readily available energy. Research describes MOTS-c interacting with the folate-methionine cycle, a metabolic pathway involved in generating the building blocks for methylation reactions and nucleotide synthesis, as part of how it triggers AMPK activation.
In animal studies, MOTS-c administration increases phosphorylated (activated) AMPK in skeletal muscle, liver, and fat tissue, which downstream is associated with increased fatty acid oxidation, improved glucose uptake, and greater mitochondrial biogenesis, essentially cells building more of their own energy-producing machinery. Separately, human observational research has found that MOTS-c rises sharply in skeletal muscle after acute exercise, which has led researchers to describe it as part of the signaling that links physical activity to metabolic adaptation, though this line of evidence shows association during natural exercise rather than proving cause and effect from external MOTS-c administration.
What research suggests
Animal and cellular studies suggest metabolic benefits under stress or high-fat diet conditions. Human clinical literature is limited compared with GLP-1 class drugs.
Reported benefits
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
Metabolic homeostasis in animal models
The foundational 2015 study reported that MOTS-c administration reduced diet-induced obesity and insulin resistance in mice.
Exercise-linked signaling
Human studies report that acute aerobic exercise substantially raises MOTS-c in skeletal muscle and modestly in circulation, positioning it as part of the body's natural exercise-response signaling.
Age-related physical decline in mice
A 2021 study reported that MOTS-c administration in aged mice reversed some age-associated physical decline and improved insulin sensitivity.
Mitochondrial biogenesis signals
Preclinical work links MOTS-c to increased mitochondrial biogenesis and fatty acid oxidation in muscle, liver, and fat tissue, mechanisms of interest for metabolic and longevity research.
Uncertainties & risks
Translational gap from mice to humans is large. Research-chemical quality control is a practical risk. Longevity and body-composition claims online often exceed published evidence.
The evidence gap for MOTS-c is significant. Almost everything supporting its metabolic and longevity reputation comes from mouse studies or from human research observing how naturally occurring MOTS-c responds to exercise and aging, not from controlled trials of external MOTS-c administration in people. There are no completed, published human efficacy trials as of this review, which puts it meaningfully behind other metabolic peptides discussed on this site. The translational gap from mice to humans is a real and largely unresolved question here, since dosing, safety, and effect size in people have not been established through clinical trials. As an unregulated research chemical, product quality and purity are separate practical concerns on top of the thin efficacy data. Longevity and body-composition claims made about MOTS-c online often run well ahead of what has actually been published, and it is worth treating those claims as hypotheses drawn from early mechanistic and animal research rather than established findings.
STACKD study summaries
Start with our in-house roundups, plain-language synthesis of the research, with primary sources cited at the bottom of each.
Primary sources
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.